Search

Your search keyword '"Shapiro, Roger L"' showing total 9 results
Start Over Author "Shapiro, Roger L" Journal jaids: journal of acquired immune deficiency syndromes
9 results on '"Shapiro, Roger L"'

1. Brief Report: Long-Term Clinical, Immunologic, and Virologic Outcomes Among Early-Treated Children With HIV in Botswana: A Nonrandomized Controlled Clinical Trial.

Author

Ajibola, Gbolahan, Maswabi, Kenneth, Hughes, Michael D., Bennett, Kara, Pretorius-Holme, Molly, Capparelli, Edmund V., Jean-Philippe, Patrick, Moyo, Sikhulile, Mohammed, Terence, Batlang, Oganne, Sakoi, Maureen, Ricci, Lucia, Lockman, Shahin, Makhema, Joseph, Kuritzkes, Daniel R., Lichterfeld, Mathias, and Shapiro, Roger L.

Published
2023
Full Text
View/download PDF

5. High Viral Load and Elevated Angiogenic Markers Associated With Increased Risk of Preeclampsia Among Women Initiating Highly Active Antiretroviral Therapy in Pregnancy in the Mma Bana Study, Botswana.

Author

Powis, Kathleen M., McElrath, Thomas F., Hughes, Michael D., Ogwu, Anthony, Souda, Sajini, Datwyler, Saul A., von Widenfelt, Erik, Moyo, Sikhulile, Nádas, Marisa, Makhema, Joseph, Machakaire, Esther, Lockman, Shahin, Essex, Max, and Shapiro, Roger L.

Published
2013
Full Text
View/download PDF

7. Increased Risk of Severe Infant Anemia After Exposure to Maternal HAART, Botswana.

Author

Dryden-Peterson, Scott, Shapiro, Roger L, Hughes, Michael D, Powis, Kathleen, Ogwu, Anthony, Moffat, Claire, Moyo, Sikhulile, Makhema, Joseph, Essex, Max, and Lockman, Shahin

Abstract

Maternal highly-active antiretroviral therapy (HAART) reduces mother-to-child HIV transmission but may increase the risk for infant anemia.The incidence of first severe anemia (grade 3 or 4, Division of AIDS 2004 Toxicity Table) was assessed among HIV-uninfected infants in the Mashi and Mma Bana mother-to-child HIV transmission prevention trials in Botswana. Severe anemia rates were compared between 3 groups: infants exposed to maternal HAART in utero and during breastfeeding (BF) and 1 month of postnatal zidovudine (ZDV) (HAART-BF); infants exposed to maternal ZDV in utero, 6 months of postnatal ZDV, and BF (ZDV-BF); and infants exposed to maternal ZDV in utero, 1 month of postnatal ZDV, and formula-feeding (ZDV-FF).A total of 1719 infants were analyzed-691 HAART-BF, 503 ZDV-BF, and 525 ZDV-FF. Severe anemia was detected in 118 infants (7.4%). By 6 months, 12.5% of HAART-BF infants experienced severe anemia, compared with 5.3% of ZDV-BF (P < 0.001) and 2.5% of ZDV-FF infants (P < 0.001). In adjusted analysis, HAART-BF infants were at greater risk of severe anemia than ZDV-BF or ZDV-FF infants (adjusted odds ratios 2.6 and 5.8, respectively; P < 0.001). Most anemias were asymptomatic and improved with iron/multivitamin supplementation and cessation of ZDV exposure. However, 11 infants (0.6% of all infants) required transfusion for symptomatic anemia. Microcytosis and hypochromia were common among infants with severe anemia.Exposure to maternal HAART starting in utero was associated with severe infant anemia. Confirmation of this finding and possible strategies to mitigate hematologic toxicity warrant further study. [ABSTRACT FROM AUTHOR]

Published
2011
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results